NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
8 trialsNCT06090669 2026-02-17
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06655246 2026-02-05
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06889168 2026-01-21
LAMP-2
Columbia University
Phase 1 Recruiting
NCT07171203 2025-09-12
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Not yet recruiting
NCT03469011 2025-06-27
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
AHS Cancer Control Alberta
Phase 1 Terminated
NCT01751425 2025-06-03
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06962254 2025-05-08
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Phase 1 Recruiting